국제의료정보포털

제1장 연구개요 ····································································································································1

 1. 연구 배경 및 필요성 ················································································································3

 2. 연구목적 및 내용 ·····················································································································5

 3. 사례조사 대상 ···························································································································6

 4. 사례조사 항목 및 방법 ············································································································7

제2장 바이오클러스터 사례조사 ········································································································9

 1. 아시아 ·····································································································································11

 1.1 중국 베이징 중관춘생명과학단지 (Zhongguancun Life Science Park) ··············11

 1.2 중국 상하이 장지앙파마벨리(Zhangjiang Pharma Valley) ····································17

 1.3 일본 고베 의료산업도시 (Kobe Biomedical Innovation Cluster; KBIC) ··········23

 1.4 싱가포르 Tuas Biomedical Park ··············································································29

 1.5 싱가포르 바이오폴리스(Biopolis) ················································································35

 2. 북미 ·········································································································································43

 2.1 미국 노스캐롤라이나 리서치트라이앵글파크(Research Triangle Park; RTP) ······43

 2.2 미국 샌디에고 Life Science Cluster ·········································································50

 2.3 미국 텍사스 메디컬센터 (Texas Medical Center) ··················································57

 2.4 미국 보스턴 Boston Biotech Cluster ·······································································63

 2.5 미국 샌프란시스코 Bay area Biocluster ··································································71

 2.6 미국 BioHealth Capital Region (BHCR) ·······························································77

 2.7 캐나다 토론토 Medical and Related Sciences (MaRS) Discovery District ····82

3. 유럽 ·········································································································································89

 3.1 영국 Cambridge Science Park ················································································89

 3.2 스웨덴 Stockholm-Uppsala Life Science Park ····················································94

 3.3 독일 베를린-브란덴부르크 HealthCapital (Cluster Healthcare Industries

 Berlin-Brandenburg) ································································································100

 3.4 독일 라인-네카 지역 생명과학 클러스터 (Life Science Cluster Rhine-Neckar;

 BioRN) ·························································································································107

 3.5 프랑스 파리 Station F ·······························································································113

 3.6 덴마크-스웨덴 Medicon Valley ···············································································118

 3.7 스위스-프랑스-독일 BioValley Life Science Cluster ··········································123

 3.8 벨기에 바이오클러스터 ································································································128

4. 오세아니아 ····························································································································134

4.1 호주 멜버른 Melbourne Biomedical Precinct (MBP) ········································134

제3장 사례조사 결과 분석 ·············································································································141

 1. 조사 대상의 주요 특징 ·······································································································143

 1.1 설립 배경에 따른 분류 (정부주도형, 민간주도형) ····················································143

 1.2 클러스터 형태에 따른 구분 ························································································145

 1.3 대형병원이 혁신 활동에 큰 역할을 하는 클러스터 ··················································146

2. 바이오클러스터 성공 요인 도출 ·························································································149